Skip to main content
Top
Published in: BMC Gastroenterology 1/2024

Open Access 01-12-2024 | Primary Sclerosing Cholangitis | Research

Genetically predicted gut microbiota mediate the association between plasma lipidomics and primary sclerosing cholangitis

Authors: Jie Zhou, Dagang Zhu, Yixin Xu, Chao Chen, Kun Wang

Published in: BMC Gastroenterology | Issue 1/2024

Login to get access

Abstract

Background

Primary sclerosing cholangitis (PSC) is a complex disease with pathogenic mechanisms that remain to be elucidated. Previous observational studies with small sample sizes have reported associations between PSC, dyslipidemia, and gut microbiota dysbiosis. However, the causality of these associations is uncertain, and there has been no systematic analysis to date.

Methods

The datasets comprise data on PSC, 179 lipid species, and 412 gut microbiota species. PSC data (n = 14,890) were sourced from the International PSC Study Group, while the dataset pertaining to plasma lipidomics originated from a study involving 7174 Finnish individuals. Data on gut microbiota species were derived from the Dutch Microbiome Project study, which conducted a genome-wide association study involving 7738 participants. Furthermore, we employed a two-step Mendelian randomization (MR) analysis to quantify the proportion of the effect of gut microbiota-mediated lipidomics on PSC.

Results

Following a rigorous screening process, our MR analysis revealed a causal relationship between higher levels of gene-predicted Phosphatidylcholine (O-16:1_18:1) (PC O-16:1_18:1) and an increased risk of developing PSC (inverse variance-weighted method, odds ratio (OR) 1.30, 95% confidence interval (CI) 1.03–1.63). There is insufficient evidence to suggest that gene-predicted PSC impacts the levels of PC O-16:1_18:1 (OR 1.01, 95% CI 0.98–1.05). When incorporating gut microbiota data into the analysis, we found that Eubacterium rectale-mediated genetic prediction explains 17.59% of the variance in PC O-16:1_18:1 levels.

Conclusion

Our study revealed a causal association between PC O-16:1_18:1 levels and PSC, with a minor portion of the effect mediated by Eubacterium rectale. This study aims to further explore the pathogenesis of PSC and identify promising therapeutic targets. For patients with PSC who lack effective treatment options, the results are encouraging.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dyson JK, Beuers U, Jones DEJ, Lohse AW. Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391:2547–59.PubMedCrossRef Dyson JK, Beuers U, Jones DEJ, Lohse AW. Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391:2547–59.PubMedCrossRef
2.
go back to reference Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–88.PubMedCrossRef Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–88.PubMedCrossRef
3.
go back to reference Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–55.PubMedCrossRef Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–55.PubMedCrossRef
4.
go back to reference Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol. 1995;20:215–9.PubMedCrossRef Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol. 1995;20:215–9.PubMedCrossRef
5.
go back to reference Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am J Ther. 2006;13:171–4.PubMedCrossRef Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am J Ther. 2006;13:171–4.PubMedCrossRef
6.
go back to reference Banales JM, Iñarrairaegui M, Arbelaiz A, et al. Serum metabolites as diagnostic biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and primary sclerosing Cholangitis. Hepatology. 2019;70:547–62.PubMedCrossRef Banales JM, Iñarrairaegui M, Arbelaiz A, et al. Serum metabolites as diagnostic biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and primary sclerosing Cholangitis. Hepatology. 2019;70:547–62.PubMedCrossRef
7.
go back to reference Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;35:263–74.PubMedCrossRef Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;35:263–74.PubMedCrossRef
8.
go back to reference Stokkeland K, Höijer J, Bottai M, Söderberg-Löfdal K, Bergquist A. Statin use is Associated with Improved outcomes of patients with primary sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2019;17:1860–e661.PubMedCrossRef Stokkeland K, Höijer J, Bottai M, Söderberg-Löfdal K, Bergquist A. Statin use is Associated with Improved outcomes of patients with primary sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2019;17:1860–e661.PubMedCrossRef
9.
go back to reference Ottensmann L, Tabassum R, Ruotsalainen SE, et al. Genome-wide association analysis of plasma lipidome identifies 495 genetic associations. Nat Commun. 2023;14:6934.PubMedPubMedCentralCrossRef Ottensmann L, Tabassum R, Ruotsalainen SE, et al. Genome-wide association analysis of plasma lipidome identifies 495 genetic associations. Nat Commun. 2023;14:6934.PubMedPubMedCentralCrossRef
10.
13.
go back to reference Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901–8.PubMedPubMedCentralCrossRef Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901–8.PubMedPubMedCentralCrossRef
14.
15.
go back to reference Yang J, Ma G, Wang K, et al. Causal associations between gut microbiota and cholestatic liver diseases: a mendelian randomization study. Front Med (Lausanne). 2024;11:1342119.PubMedCrossRef Yang J, Ma G, Wang K, et al. Causal associations between gut microbiota and cholestatic liver diseases: a mendelian randomization study. Front Med (Lausanne). 2024;11:1342119.PubMedCrossRef
16.
go back to reference Miyajima Y, Karashima S, Ogai K, et al. Impact of gut microbiome on dyslipidemia in Japanese adults: Assessment of the Shika-Machi super preventive health examination results for causal inference. Front Cell Infect Microbiol. 2022;12:908997.PubMedPubMedCentralCrossRef Miyajima Y, Karashima S, Ogai K, et al. Impact of gut microbiome on dyslipidemia in Japanese adults: Assessment of the Shika-Machi super preventive health examination results for causal inference. Front Cell Infect Microbiol. 2022;12:908997.PubMedPubMedCentralCrossRef
17.
go back to reference Wan X, Li T, Liu D et al. Effect of Marine Microalga Chlorella pyrenoidosa ethanol extract on lipid metabolism and gut microbiota composition in High-Fat Diet-Fed rats. Mar Drugs. 2018; 16. Wan X, Li T, Liu D et al. Effect of Marine Microalga Chlorella pyrenoidosa ethanol extract on lipid metabolism and gut microbiota composition in High-Fat Diet-Fed rats. Mar Drugs. 2018; 16.
18.
go back to reference Panyod S, Wu WK, Hu MY, et al. Healthy diet intervention reverses the progression of NASH through gut microbiota modulation. Microbiol Spectr. 2024;12:e0186823.PubMedCrossRef Panyod S, Wu WK, Hu MY, et al. Healthy diet intervention reverses the progression of NASH through gut microbiota modulation. Microbiol Spectr. 2024;12:e0186823.PubMedCrossRef
19.
go back to reference He X, Chen D, Guo Y, et al. Walnut Meal extracts Rich in polyphenols mitigate insulin resistance and modulate gut microbiota in high Fat Diet-Fed rats. J Med Food. 2022;25:618–29.PubMedCrossRef He X, Chen D, Guo Y, et al. Walnut Meal extracts Rich in polyphenols mitigate insulin resistance and modulate gut microbiota in high Fat Diet-Fed rats. J Med Food. 2022;25:618–29.PubMedCrossRef
21.
22.
go back to reference Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49:269–73.PubMedCrossRef Ji SG, Juran BD, Mucha S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49:269–73.PubMedCrossRef
23.
go back to reference Lopera-Maya EA, Kurilshikov A, van der Graaf A, et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat Genet. 2022;54:143–51.PubMedCrossRef Lopera-Maya EA, Kurilshikov A, van der Graaf A, et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat Genet. 2022;54:143–51.PubMedCrossRef
24.
go back to reference Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7.
25.
go back to reference Burgess S, Thompson SG. Avoiding bias from weak instruments in mendelian randomization studies. Int J Epidemiol. 2011;40:755–64.PubMedCrossRef Burgess S, Thompson SG. Avoiding bias from weak instruments in mendelian randomization studies. Int J Epidemiol. 2011;40:755–64.PubMedCrossRef
26.
go back to reference Broadbent JR, Foley CN, Grant AJ, et al. MendelianRandomization v0.5.0: updates to an R package for performing mendelian randomization analyses using summarized data. Wellcome Open Res. 2020;5:252.PubMedPubMedCentralCrossRef Broadbent JR, Foley CN, Grant AJ, et al. MendelianRandomization v0.5.0: updates to an R package for performing mendelian randomization analyses using summarized data. Wellcome Open Res. 2020;5:252.PubMedPubMedCentralCrossRef
27.
go back to reference Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.PubMedPubMedCentralCrossRef Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.PubMedPubMedCentralCrossRef
28.
go back to reference Zhao J, Ming J, Hu X, et al. Bayesian weighted mendelian randomization for causal inference based on summary statistics. Bioinformatics. 2020;36:1501–08.PubMedCrossRef Zhao J, Ming J, Hu X, et al. Bayesian weighted mendelian randomization for causal inference based on summary statistics. Bioinformatics. 2020;36:1501–08.PubMedCrossRef
29.
go back to reference Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14.PubMedPubMedCentralCrossRef Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14.PubMedPubMedCentralCrossRef
30.
go back to reference Zhang Y, Liu Z, Choudhury T, Cornelis MC, Liu W. Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample mendelian randomization study. Eur J Nutr. 2021;60:1761–67.PubMedCrossRef Zhang Y, Liu Z, Choudhury T, Cornelis MC, Liu W. Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample mendelian randomization study. Eur J Nutr. 2021;60:1761–67.PubMedCrossRef
31.
go back to reference Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465–78.PubMedPubMedCentralCrossRef Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465–78.PubMedPubMedCentralCrossRef
32.
go back to reference van Kippersluis H, Rietveld CA. Pleiotropy-robust mendelian randomization. Int J Epidemiol. 2018;47:1279–88.PubMedCrossRef van Kippersluis H, Rietveld CA. Pleiotropy-robust mendelian randomization. Int J Epidemiol. 2018;47:1279–88.PubMedCrossRef
33.
go back to reference Yin KJ, Huang JX, Wang P, et al. No Genetic Causal Association between Periodontitis and Arthritis: a bidirectional two-sample mendelian randomization analysis. Front Immunol. 2022;13:808832.PubMedPubMedCentralCrossRef Yin KJ, Huang JX, Wang P, et al. No Genetic Causal Association between Periodontitis and Arthritis: a bidirectional two-sample mendelian randomization analysis. Front Immunol. 2022;13:808832.PubMedPubMedCentralCrossRef
34.
go back to reference Ooi GJ, Meikle PJ, Huynh K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75:524–35.PubMedCrossRef Ooi GJ, Meikle PJ, Huynh K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75:524–35.PubMedCrossRef
35.
go back to reference Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748–66.PubMedCrossRef Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748–66.PubMedCrossRef
36.
go back to reference Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18:835–56.PubMedCrossRef Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18:835–56.PubMedCrossRef
38.
go back to reference Trottier J, Białek A, Caron P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012;44:303–10.PubMedCrossRef Trottier J, Białek A, Caron P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012;44:303–10.PubMedCrossRef
39.
go back to reference Benítez-Páez A, Kjølbæk L, Del Gómez EM et al. A multi-omics Approach to unraveling the microbiome-mediated effects of Arabinoxylan oligosaccharides in overweight humans. mSystems. 2019; 4. Benítez-Páez A, Kjølbæk L, Del Gómez EM et al. A multi-omics Approach to unraveling the microbiome-mediated effects of Arabinoxylan oligosaccharides in overweight humans. mSystems. 2019; 4.
40.
go back to reference Stremmel W, Staffer S, Gan-Schreier H, et al. Phosphatidylcholine passes through lateral tight junctions for paracellular transport to the apical side of the polarized intestinal tumor cell-line CaCo2. Biochim Biophys Acta. 2016;1861:1161–69.PubMedCrossRef Stremmel W, Staffer S, Gan-Schreier H, et al. Phosphatidylcholine passes through lateral tight junctions for paracellular transport to the apical side of the polarized intestinal tumor cell-line CaCo2. Biochim Biophys Acta. 2016;1861:1161–69.PubMedCrossRef
41.
go back to reference Stremmel W, Staffer S, Schneider MJ, et al. Genetic mouse models with intestinal-specific tight Junction deletion resemble an Ulcerative Colitis phenotype. J Crohns Colitis. 2017;11:1247–57.PubMedPubMedCentralCrossRef Stremmel W, Staffer S, Schneider MJ, et al. Genetic mouse models with intestinal-specific tight Junction deletion resemble an Ulcerative Colitis phenotype. J Crohns Colitis. 2017;11:1247–57.PubMedPubMedCentralCrossRef
42.
go back to reference Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-tandem mass spectrometry. Scand J Gastroenterol. 2004;39:737–42.PubMedCrossRef Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-tandem mass spectrometry. Scand J Gastroenterol. 2004;39:737–42.PubMedCrossRef
43.
go back to reference Braun A, Treede I, Gotthardt D, et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis. 2009;15:1705–20.PubMedCrossRef Braun A, Treede I, Gotthardt D, et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis. 2009;15:1705–20.PubMedCrossRef
44.
go back to reference Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67:615–23.PubMedCrossRef Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67:615–23.PubMedCrossRef
45.
go back to reference Feingold KR, Grunfeld C. The effect of inflammation and infection on lipids and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2024. MDText.com, Inc.; 2000. Feingold KR, Grunfeld C. The effect of inflammation and infection on lipids and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2024. MDText.com, Inc.; 2000.
46.
go back to reference Gauss A, Ehehalt R, Lehmann WD, et al. Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis. World J Gastroenterol. 2013;19:5454–63.PubMedPubMedCentralCrossRef Gauss A, Ehehalt R, Lehmann WD, et al. Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis. World J Gastroenterol. 2013;19:5454–63.PubMedPubMedCentralCrossRef
47.
48.
go back to reference Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol. 1995;57:565–83.PubMedCrossRef Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol. 1995;57:565–83.PubMedCrossRef
49.
go back to reference Stremmel W, Staffer S, Weiskirchen R. Phosphatidylcholine passes by Paracellular Transport to the apical side of the polarized biliary tumor cell line Mz-ChA-1. Int J Mol Sci. 2019; 20. Stremmel W, Staffer S, Weiskirchen R. Phosphatidylcholine passes by Paracellular Transport to the apical side of the polarized biliary tumor cell line Mz-ChA-1. Int J Mol Sci. 2019; 20.
50.
go back to reference Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018;362:776–80.PubMedCrossRef Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018;362:776–80.PubMedCrossRef
51.
go back to reference Qiao F, Tan F, Li LY, et al. Alteration and the function of Intestinal Microbiota in High-Fat-Diet- or Genetics-Induced lipid Accumulation. Front Microbiol. 2021;12:741616.PubMedPubMedCentralCrossRef Qiao F, Tan F, Li LY, et al. Alteration and the function of Intestinal Microbiota in High-Fat-Diet- or Genetics-Induced lipid Accumulation. Front Microbiol. 2021;12:741616.PubMedPubMedCentralCrossRef
52.
go back to reference Mehta TI, Weissman S, Fung BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Int. 2021;41:2418–26.PubMedCrossRef Mehta TI, Weissman S, Fung BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Int. 2021;41:2418–26.PubMedCrossRef
Metadata
Title
Genetically predicted gut microbiota mediate the association between plasma lipidomics and primary sclerosing cholangitis
Authors
Jie Zhou
Dagang Zhu
Yixin Xu
Chao Chen
Kun Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03246-3

Other articles of this Issue 1/2024

BMC Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.